Oclacitinib 10 years later: lessons learned and directions for the future

Marsella, Rosanna; Doerr, Katherine; Gonzales, Andrea J.; Rosenkrantz, Wayne; Schissler, Jennifer R.; White, Andrew

doi:10.2460/javma.22.12.0570

Cited by 3 publications

(3 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A variety of JAK inhibitors are currently on the market or under clinical studies (see Table 1), and these drugs have different target selectivity [10,16]. Tofacitinib, targeting JAK 1 and JAK 3, is the world's first JAK inhibitor approved for clinical use [17,18], and has shown encouraging efficacy in a variety of autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and polyarticular juvenile idiopathic arthritis [7,8,19].…”

Section: Jak/stat Signaling Pathway and Jak Inhibitorsmentioning

confidence: 99%

“…In the report by Kröger et al, [47] 12 MF patients who continued RUX (2-5 mg per day) during transplantation until stable engraftment, with median exposure of 163 days to RUX prior to transplantation, all showed improvement in spleen size and physical symptoms, and all achieved successful engraftment. The median time to leukocyte engraftment was 12 days (range [11][12][13][14][15][16][17][18]. After a median of 40 days, 11 patients achieved complete donor chimerism, and after a median of 32 days, molecular clearance of potential driver mutations (JAK2V617F, CALR, or MPL) was noted in 10 patients.…”

Section: Application Of Other Jak Inhibitorsmentioning

confidence: 99%

See 1 more Smart Citation

The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis

Wang,

Jin,

Zeng

et al. 2024

Ann Hematol

View full text Add to dashboard Cite

Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with a poor prognosis, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment with curative potential. Ruxolitinib, a JAK1/2 inhibitor, has shown promising results in improving patients’ symptoms, overall survival, and quality of life, and can be used as a bridging therapy to HSCT that increases the proportion of transplantable patients. However, the effect of this and similar drugs on HSCT outcomes is unknown, and the reports on their efficacy and safety in the peri-transplantation period vary widely in the published literature. This paper reviews clinical data related to the use of JAK inhibitors in the peri-implantation phase of hematopoietic stem cell transplantation for primary myelofibrosis and discusses their efficacy and safety.

show abstract

Section: Jak/stat Signaling Pathway and Jak Inhibitorsmentioning

confidence: 99%

Section: Application Of Other Jak Inhibitorsmentioning

confidence: 99%

The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis

Wang,

Jin,

Zeng

et al. 2024

Ann Hematol

View full text Add to dashboard Cite

show abstract

“…Monoclonal antibodies, such as lokivetmabum, which are gaining more and more favour, are more suitable for therapy [8], which was also confirmed by the interviewed veterinarians. The drug oclacitinib has a great future worldwide due to its high effectiveness in the therapy of atopic dermatitis [5,6,12]. Up to 64 % of veterinarians confirmed the use of oclacitinib in their practice.…”

Section: Dermatoses Associated With Hormonal Disordersmentioning

confidence: 99%

Dermatological Diseases in Dogs ‒ A Survey in Veterinary Facilities

Malinovská,

Fekeová

2023

Folia Veterinaria

View full text Add to dashboard Cite

Skin diseases in dogs are very often the reason for visiting the veterinarian. For the successful management of a dermatological disease, accurate diagnosis, correct setting of the treatment and cooperation of the owner are necessary. This article provides a summary of information related to the diagnosis and treatment of skin diseases in dogs obtained from 50 veterinary facilities in Slovakia. In the monitored veterinary facilities, the most common dermatoses are skin diseases due to immune disorders, followed by bacterial and parasitic skin diseases. For the prevention of external parasites (ticks, fleas), tablets containing fluralaner, sarolaner and afoxolaner are increasingly preferred, even though spot-on preparations, especially those containing fipronil, maintain a constant position in prevention. Among the most commonly used ATBs in the treatment of skin bacterial infections are amoxicillin with clavulanic acid and cephalexin. Currently, the veterinary medicine with the active substance oclacitinib and the medicine containing lokivetmab are coming to the fore in the treatment of allergies in dogs, while veterinarians are trying to limit the use of glucocorticoids.

show abstract

Canine neutrophile Dermatose (Sweet-like Syndrom): Eine Beschreibung von 3 Fällen

Schönbach,

Thom,

Mathes

et al. 2024

Tierarztl Prax Ausg K Kleintiere Heimtiere

View full text Add to dashboard Cite

ZusammenfassungEs wurden 3 Hunde mit plötzlich auftretenden erythematösen Hautveränderungen, Fieber und weiteren unterschiedlichen extrakutanen Symptomen vorgestellt, welche mittels klinischer, labordiagnostischer und histopathologischer Untersuchungen der caninen sterilen neutrophilen Dermatose zugeordnet werden konnten. Die Erkrankung ist sehr selten und mit dem Sweet-Syndrom (SS) des Menschen zu vergleichen. Entsprechend den 4 Formen des SS konnte in dieser Kasuistik der 1. und 3. Fall dem klassischen/idiopathischen SS zugeordnet werden, wobei die respiratorischen Symptome, als Prodromalstadium des SS, den Hautläsionen vorausgingen oder eine Infektion des Respirationstraktes als Trigger des SS anzusprechen ist. Der 2. Fall hingegen weist einen deutlichen und der 3. Fall einen möglichen Zusammenhang mit Pathergie als Folge einer vorausgegangen chirurgischen Versorgung (Fall 2 eine Tibia Plateau Leveling Osteotomy [TPLO] 20 Tage zuvor; Fall 3 eine Hemilaminektomie 90 Tage zuvor) auf, wodurch beide der 4. Form des SS zugeordnet werden können. Bei allen 3 Fällen ist eine adverse Arzneimittelreaktion als Trigger nicht sicher auszuschließen, da jeweils vor Diagnosestellung Medikamente eingesetzt wurden. Neben den häufigsten extrakutanen Symptomen wie Fieber und Neutrophilie, trat bei 2 der Patienten eine immunhämolytische Anämie auf. Als Therapieoptionen wird zusätzlich zu den etablierten immunsupprimierenden Medikamenten wie Prednisolon, Ciclosporin und Azathioprin auch Oclacitinib in das Behandlungsschema mit aufgenommen, ebenso wie ein Thrombozytenaggregationshemmer (Clopidogrel), welcher als Lehre aus dem 1. der vorliegenden Fälle zu deuten ist, der an einer pulmonalen Thromboembolie verstarb. Bei Fall 2 konnten alle Medikamente über 2,5 Jahre ausgeschlichen werden, seit 4 Jahren ist der Patient ohne Rezidiv. Fall 3 ist unter Therapie rezidivfrei.

show abstract

Oclacitinib 10 years later: lessons learned and directions for the future

Cited by 3 publications

References 46 publications

The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis

The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis

Dermatological Diseases in Dogs ‒ A Survey in Veterinary Facilities

Canine neutrophile Dermatose (Sweet-like Syndrom): Eine Beschreibung von 3 Fällen

Contact Info

Product

Resources

About